Form 4: IGM Biosciences Executive Bruce Keyt Reports Changes in Beneficial Ownership After Option Exchange

Bruce Keyt, Chief Scientific Officer of IGM Biosciences, reports changes in beneficial ownership due to an option exchange program, resulting in the acquisition of restricted stock units (RSUs) and cancellation of stock options.

Summary

• On July 19, 2024, Bruce Keyt, the Chief Scientific Officer of IGM Biosciences, engaged in transactions involving the company's stock.
• Keyt acquired 43,888 RSUs, which vest over time, contingent on continued service.
• He also acquired 2,778 RSUs with a different vesting schedule.
• These transactions were part of IGM Biosciences' option exchange program, where Keyt's options to purchase 75,000 and 50,000 shares were cancelled.
• Following these transactions, Keyt directly owns 244,435 shares of common stock and indirectly owns 4,039 shares through his spouse.
• Keyt's direct ownership also includes 0 derivative securities after the cancellation of options to purchase 75,000 and 50,000 shares of common stock.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing executive compensation adjustments. It doesn't contain overtly positive or negative information, hence a neutral sentiment score.

Positives

• The option exchange program may align executive incentives with long-term company performance through RSU grants.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person remaining a service provider through each vesting date.

Industry Context

Option exchange programs are a common practice in the biotech industry to refresh employee incentives and align them with company goals, often replacing older options with newer equity grants like RSUs.

Comparison to Industry Standards

• Option exchange programs are common in the biotech industry, with companies like Amgen and Gilead Sciences also utilizing similar strategies to manage employee equity incentives.
• The vesting schedules for the RSUs appear to be fairly standard, aligning with typical vesting periods observed in similar companies.

Stakeholder Impact

• The option exchange program and RSU grants may have a minor dilutive effect on existing shareholders.
• The transactions are designed to incentivize the Chief Scientific Officer, potentially benefiting shareholders through improved company performance.

Key Dates